---
title: >-
  Factors Associated with Biologic Discontinuation in Patients with Inflammatory
  Bowel Disease in TARGET-IBD.
description: >-
  Explore this publication on real-world evidence: Factors Associated with
  Biologic Discontinuation in Patients with Inflammatory Bowel Disease in
  TARGET-IBD..
date: '2020-01-01'
category: Publications
tags:
  - AIBD Conference
  - Poster Presentation
  - R&D
  - Care
  - Gastroenterology
  - IBD
  - Pharma Partner
  - Health System Partner
canonical_url: >-
  https://www.pedestalhealth.com/resources/publications/aibd-conference/factors-associated-with-biologic-discontinuation-in/
source: Pedestal Health
license: © 2026 Pedestal Health. All rights reserved.
slug: factors-associated-with-biologic-discontinuation-in
id: 1QUKAe9NTr4oukReyJ9KBs
contentType: article
---

## Challenge

A substantial proportion of IBD patients discontinue biologic therapy within 12 months, but the real-world predictors of biologic discontinuation—separately for CD and UC—had not been characterized in a large prospective US cohort, limiting understanding of durability challenges in routine care.

## Solution

The TARGET-IBD registry was used to analyze time to biologic discontinuation and its predictors across CD and UC patients using Kaplan-Meier survival analysis and multivariable Cox proportional hazards regression, funded by AbbVie and Bristol Myers Squibb.

## Impact

Establishing that nearly one-third of IBD patients discontinue biologic therapy—with secondary loss of response as the leading driver—provides real-world evidence of the durability gap that next-generation IBD therapies must address, directly informing drug development programs and prescriber strategies for optimizing biologic durability.

### [Julie M. Crawford](/people/julie-crawford/)